Reasons for Zepbound (tirzepatide) Coverage Denial

Understanding the common reasons for insurance denial of Zepbound coverage can help you navigate the appeals process.

Common Denial Reasons

Insurance plans may deny coverage for Zepbound (tirzepatide) for several reasons. One primary reason is that the plan excludes weight-loss drugs entirely, categorizing them as 'anti-obesity medications' which are often not covered under many employer and Medicare plans. This type of denial is typically a benefit-design issue rather than a clinical one.

Another common reason for denial is insufficient documentation of the patient's Body Mass Index (BMI) or related comorbidities at the time of the request. For instance, if a patient has a BMI of 27 but does not have documented weight-related conditions such as hypertension or type 2 diabetes, the request may be denied.

Additionally, if the patient has not completed or documented required step therapy (trying a preferred or cheaper drug first), this can also lead to a denial. Requests for off-label uses, such as using a diabetes-only drug for weight loss, are another frequent cause of rejection.

Lastly, if the requested drug is not included on the plan's formulary or if there is a preferred GLP-1 medication, the request may be denied.

Next Steps After Denial

If your coverage for Zepbound has been denied, consider following the appeal ladder. Start with an internal appeal by submitting a letter of medical necessity that ties your documented medical record to each criterion required by your insurance plan. If that does not succeed, a peer-to-peer review can be initiated where your prescriber speaks directly with the plan's medical director. If further documentation becomes available, you may proceed with a second internal appeal. For denials that hinge on benefit exclusions, pivoting to a covered indication or exploring cash-pay options may be necessary.